Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Sep 3:15:53.
doi: 10.1186/s13223-019-0366-x. eCollection 2019.

Efficacy of add-on mepolizumab in adolescents with severe eosinophilic asthma

Steven W Yancey  1 , Hector G Ortega  2   3 , Oliver N Keene  4 , Eric S Bradford  1
Affiliations

Efficacy of add-on mepolizumab in adolescents with severe eosinophilic asthma

Steven W Yancey et al. Allergy Asthma Clin Immunol. .

Abstract

Adolescents (12-17 years of age) with severe eosinophilic asthma experience frequent exacerbations and reduced lung function leading to poor health-related quality of life. Mepolizumab is approved for add-on maintenance therapy in patients with severe eosinophilic asthma ≥ 6 years of age in the EU and ≥ 12 years of age in other regions (including the USA), based on a Phase II/III program demonstrating reduced exacerbation rates with 4-weekly treatment. A total of 34 adolescent patients were recruited across the Phase III mepolizumab trials. Consistent with outcomes in the overall population, there was a reduction in the annual rate of clinically significant exacerbations, along with a reduction in blood eosinophil counts in response to mepolizumab in adolescent patients. The safety profile in adolescent patients was consistent with that seen in the overall population. Data from the Phase III clinical development program provide evidence for comparable efficacy and safety of mepolizumab between adolescents with severe eosinophilic asthma and the overall population. Clinical trial registration DREAM, NCT01000506 [MEA112997]; MENSA, NCT01691521 [MEA115588]; SIRIUS, NCT01691508 [MEA115575]; MUSCA, NCT02281318 [200862]; COSMOS, NCT01842607 [MEA115661].

Keywords: Adolescent; Asthma control; Eosinophils; Exacerbations; Mepolizumab; Severe eosinophilic asthma.

PubMed Disclaimer

Conflict of interest statement

Competing interestsSWY, ONK, and ESB are GSK employees and hold GSK stocks/shares. HGO was an employee of GSK during the time of the analysis and is now employed by Gossamer Bio.

Figures

Fig. 1
Fig. 1
Clinically significant exacerbation rate/year in adolescent and adult patients in the MENSA and MUSCA trials. Analyses were conducted using a negative binomial regression model including covariates for use of maintenance oral corticosteroids, geographic region, number of exacerbations in the previous year, baseline percentage of the predicted FEV1 (MENSA and MUSCA) and treatment (MENSA only). Increases in 95% CIs observed in adolescent groups are a result of the smaller sample size when compared with ≥ 18 years; CI: confidence interval; FEV1: forced expiratory volume in 1 s
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

  • Anti-IL-5 Pathway Agents in Eosinophilic-Associated Disorders Across the Lifespan.
    Lombardi C, Comberiati P, Ridolo E, Cottini M, Yacoub MR, Casagrande S, Riccò M, Bottazzoli M, Berti A. Lombardi C, et al. Drugs. 2024 Jun;84(6):661-684. doi: 10.1007/s40265-024-02037-0. Epub 2024 Jun 8. Drugs. 2024. PMID: 38849701 Free PMC article. Review.
  • Mepolizumab for urban children with exacerbation-prone eosinophilic asthma in the USA (MUPPITS-2): a randomised, double-blind, placebo-controlled, parallel-group trial.
    Jackson DJ, Bacharier LB, Gergen PJ, Gagalis L, Calatroni A, Wellford S, Gill MA, Stokes J, Liu AH, Gruchalla RS, Cohen RT, Makhija M, Khurana Hershey GK, O'Connor GT, Pongracic JA, Sherenian MG, Rivera-Spoljaric K, Zoratti EM, Teach SJ, Kattan M, Dutmer CM, Kim H, Lamm C, Sheehan WJ, Segnitz RM, Dill-McFarland KA, Visness CM, Becker PM, Gern JE, Sorkness CA, Busse WW, Altman MC; US National Institute of Allergy and Infectious Disease's Inner City Asthma Consortium. Jackson DJ, et al. Lancet. 2022 Aug 13;400(10351):502-511. doi: 10.1016/S0140-6736(22)01198-9. Lancet. 2022. PMID: 35964610 Free PMC article. Clinical Trial.
  • Difficult and Severe Asthma in Children.
    Porcaro F, Ullmann N, Allegorico A, Di Marco A, Cutrera R. Porcaro F, et al. Children (Basel). 2020 Dec 10;7(12):286. doi: 10.3390/children7120286. Children (Basel). 2020. PMID: 33322016 Free PMC article. Review.
  • Expert meeting report: towards a joint European roadmap to address the unmet needs and priorities of paediatric asthma patients on biologic therapy.
    Golebski K, Dankelman LHM, Björkander S, Bønnelykke K, Brinkman P, Deschildre A, van Dijk YE, Fleming L, Grigg J, Hamelmann E, Hashimoto S, Kabesch M, Klevebro S, Maitland-van der Zee AH, Merid SK, Nieto A, Niggel J, Nilsson C, Potočnik U, Roberts G, Rusconi F, Saglani S, Valente E, van Drunen C, Wang G, Melén E, Vijverberg SJH. Golebski K, et al. ERJ Open Res. 2021 Nov 1;7(4):00381-2021. doi: 10.1183/23120541.00381-2021. eCollection 2021 Oct. ERJ Open Res. 2021. PMID: 34729368 Free PMC article.
  • Biologicals in childhood severe asthma: the European PERMEABLE survey on the status quo.
    Santos-Valente E, Buntrock-Döpke H, Abou Taam R, Arasi S, Bakirtas A, Lozano Blasco J, Bønnelykke K, Craiu M, Cutrera R, Deschildre A, Elnazir B, Fleming L, Frey U, Gappa M, Nieto García A, Skamstrup Hansen K, Hanssens L, Jahnz-Rozyk K, Jesenak M, Kerzel S, Kopp MV, Koppelman GH, Krivec U, MacLeod KA, Mäkelä M, Melén E, Mezei G, Moeller A, Moreira A, Pohunek P, Minić P, Rutjes NWP, Sammut P, Schwerk N, Szépfalusi Z, Turkalj M, Tzotcheva I, Ulmeanu A, Verhulst S, Xepapadaki P, Niggel J, Vijverberg S, Maitland-van der Zee AH, Potočnik U, Reinartz SM, van Drunen CM, Kabesch M. Santos-Valente E, et al. ERJ Open Res. 2021 Aug 16;7(3):00143-2021. doi: 10.1183/23120541.00143-2021. eCollection 2021 Jul. ERJ Open Res. 2021. PMID: 34409097 Free PMC article.
See all "Cited by" articles

References

    1. Sears MR. Descriptive epidemiology of asthma. Lancet. 1997;350(Suppl 2):Sii1–Sii4. doi: 10.1016/S0140-6736(97)90028-3. - DOI - PubMed
    1. Lee YJ, Kim KW, Choi BS, Sohn MH, Kim KE. Clinical characteristics of eosinophilic and noneosinophilic asthma in children. Acta Paediatr. 2013;102(1):53–57. doi: 10.1111/apa.12046. - DOI - PubMed
    1. Chipps BE, Szefler SJ, Simons FE, Haselkorn T, Mink DR, Deniz Y, et al. Demographic and clinical characteristics of children and adolescents with severe or difficult-to-treat asthma. J Allergy Clin Immunol. 2007;119(5):1156–1163. doi: 10.1016/j.jaci.2006.12.668. - DOI - PubMed
    1. Lovett CJ, Whitehead BF, Gibson PG. Eosinophilic airway inflammation and the prognosis of childhood asthma. Clin Exp Allergy. 2007;37(11):1594–1601. doi: 10.1111/j.1365-2222.2007.02839.x. - DOI - PubMed
    1. Dolan CM, Fraher KE, Bleecker ER, Borish L, Chipps B, Hayden ML, et al. Design and baseline characteristics of the epidemiology and natural history of asthma: outcomes and Treatment Regimens (TENOR) study: a large cohort of patients with severe or difficult-to-treat asthma. Ann Allergy Asthma Immunol. 2004;92(1):32–39. doi: 10.1016/S1081-1206(10)61707-3. - DOI - PubMed

Associated data